Methods to enhance T-cell mediated immune response
The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age.
1 . A method of restoring T cell-mediated immune response to an exogenous immunogen in an individual whose immune response is compromised, the method comprising:
administering a pharmaceutical composition comprising a modulator of activity or expression of at least one dual specificity phosphatase to said individual in a therapeutically effective amount and within a predetermined time period before, during or after administration of said immunogen; administering said immunogen to said individual.
2 . The method of claim 1 , wherein said individual is of advanced age.
3 . The method of claim 1 , wherein said individual is of middle age.
4 . The method of claim 1 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4, 5 or 6.
5 - 9 . (canceled)
10 . The method of claim 1 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4 and 5.
11 . The method of claim 1 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4 and 6.
12 . The method of claim 1 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4, 5 and 6.
13 . The method of claim 1 , wherein said modulator is a pharmacological inhibitor of said at least one dual specificity phosphatase 1, 4, 5 or 6.
14 . The method of claim 1 , wherein said modulator downregulates the expression of said at least one dual specificity phosphatase 1, 4, 5 or 6.
15 . The method of claim 1 , wherein said administration is oral, systemic or local.
16 . A method of enhancing T cell-mediated immune response to an exogenous immunogen in an individual whose immune response is compromised, the method comprising:
administering a pharmaceutical composition comprising a modulator of activity or expression of at least one dual specificity phosphatase to said individual in a therapeutically effective amount and within a predetermined time period before, during or after administration of said immunogen; administering said immunogen to said individual.
17 . The method of claim 16 , wherein said individual is of advanced age.
18 . The method of claim 16 , wherein said individual is of middle age.
19 . The method of claim 16 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4, 5 or 6.
20 - 24 . (canceled)
25 . The method of claim 16 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4 and 5.
26 . The method of claim 16 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4 and 6.
27 . The method of claim 16 , wherein said at least one dual specificity phosphatase is dual specificity phosphatase 1, 4, 5 and 6.
28 . The method of claim 16 , wherein said modulator is a pharmacological inhibitor of said at least one dual specificity phosphatase 1, 4, 5 or 6.
29 . The method of claim 16 , wherein said modulator downregulates the expression of said at least one dual specificity phosphatase 1, 4, 5 or 6.
30 . The method of claim 16 , wherein said administration is oral, systemic or local.